Locations:
Search IconSearch

Cancer

Chris Weight typing into laptop in office

Artificial Intelligence Tool Informs Prostate Cancer Management

AI histologic classifier reliably predicts clinical risk in men post-prostatectomy

Oncologist consulting with couple
April 29, 2025/Cancer/News & Insight

Are Your Patients With Cancer Experiencing Sexual Dysfunction? Just Ask!

Sexual disorders affect patients across all cancer types

Dr. Khorana
April 25, 2025/Cancer/News & Insight

Molecular Insights into Early-Onset Biliary Tract Cancer (Podcast)

A call for awareness about the importance of genomic testing

Dr. Melenhorst
April 24, 2025/Cancer/Blood Cancers

Explore Developments in CAR T-Cell Therapy for CLL (Podcast)

Discussing research into improving CAR T-cell therapy efficacy

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Dr. Cherian
April 23, 2025/Cancer/Radiation Oncology

De-intensifying Radiation Therapy in Low-Risk Breast Cancer

Ultra-Hypofractionated Whole Breast Irradiation and Partial Breast Irradiation Reduce Many Toxicities

Pathology image
April 22, 2025/Cancer/News & Insight

Patient Case Study: Second Opinion Reveals Misdiagnosed Cancer

Patient receives liver transplant and a new lease on life

Clinician talking with patient
April 21, 2025/Cancer/News & Insight

Hematology Clinic Created to Support Spanish-Speaking Population

Lutheran Hospital team brings emerging treatments to community setting

Dr. Pennell
April 10, 2025/Cancer/News & Insight

BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Immune checkpoint inhibitor illustration
April 8, 2025/Cancer

Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

Dr. Gerds with a patient
April 7, 2025/Cancer/Blood Cancers

Positive Results from Phase 3 Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

BackPage 10 of 88Next

Advertisement

Ad